This content is machine translated Type 2 diabetes Updated SGED treatment recommendations published In recent years, the therapeutic landscape for type 2 diabetes has changed significantly. Because GLP-1 receptor agonists and SGLT-2 inhibitors have shown direct effects on cardiorenal protection in cardiovascular endpoint…
View Post 5 min This content is machine translated Type 2 diabetes Prevention of macrovascular complications – an update. Reducing the risk of microvascular and macrovascular sequelae is an important treatment goal in diabetes. In recent years, new modern drugs have entered the market that have demonstrated additional benefits…
View Post 4 min This content is machine translated Type 2 diabetes “Swiss Diabetes Guide” – digital tool supports physicians in drug selection The treatment options for type 2 diabetes mellitus are very complex. In addition to the large number of new active ingredients on the market, the scientific data base is constantly…
View Post 4 min This content is machine translated SGLT-2 inhibitors and GLP-1-RA How they can protect against diabetic sequelae In recent years, numerous new glucose-lowering agents have been developed. SGLT-2 inhibitors and GLP-1 receptor agonists have demonstrated cardiovascular and nephroprotective effects in large clinical endpoint studies. The variety of…
View Post 4 min This content is machine translated Heart failure SGLT2 inhibitors – are the new preparations more than just good antidiabetic agents? SGLT2 inhibitors have been used successfully for some time in the treatment of diabetes mellitus. They are associated with effective blood glucose lowering through increased renal glucose excretion. But they…
View Post 5 min This content is machine translated Diabetes Therapy State of the art – what do you need to know about the new active ingredients? At the Swiss Family Docs conference at the Kongresshaus Zurich, the topic of diabetes was also addressed. In a comprehensive and detailed overview, Prof. Roger Lehmann, MD, Zurich, presented the…
View Post 3 min This content is machine translated Type 2 diabetes SGLT-2 inhibitors: a new oral therapy option Dapagliflozin, a potent new selective SGLT-2 inhibitor, is available in many countries for use in type 2 diabetes patients either as add-on combination therapy when other glucose-lowering medical agents together…
View Post 9 min This content is machine translated How to treat diabetes? This is how the music of the future sounds Some new drugs and new techniques are expected to improve glycemic control in type 1 and type 2 diabetes. In addition to proper medication selection, a patient-centered approach is essential.…
